Avacincaptad pegol sodium - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for avacincaptad pegol sodium and what is the scope of freedom to operate?
Avacincaptad pegol sodium
is the generic ingredient in one branded drug marketed by Astellas and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.Avacincaptad pegol sodium has one hundred and two patent family members in twenty-seven countries.
One supplier is listed for this compound.
Summary for avacincaptad pegol sodium
| International Patents: | 102 |
| US Patents: | 9 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | avacincaptad pegol sodium at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for avacincaptad pegol sodium
Generic Entry Date for avacincaptad pegol sodium*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVITREAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for avacincaptad pegol sodium
| Drug Class | Complement Inhibitor |
| Mechanism of Action | Complement Inhibitors |
US Patents and Regulatory Information for avacincaptad pegol sodium
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astellas | IZERVAY | avacincaptad pegol sodium | SOLUTION;INTRAVITREAL | 217225-001 | Aug 4, 2023 | RX | Yes | Yes | 7,538,211 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Astellas | IZERVAY | avacincaptad pegol sodium | SOLUTION;INTRAVITREAL | 217225-001 | Aug 4, 2023 | RX | Yes | Yes | 7,579,456 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Astellas | IZERVAY | avacincaptad pegol sodium | SOLUTION;INTRAVITREAL | 217225-001 | Aug 4, 2023 | RX | Yes | Yes | 7,803,931 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Astellas | IZERVAY | avacincaptad pegol sodium | SOLUTION;INTRAVITREAL | 217225-001 | Aug 4, 2023 | RX | Yes | Yes | 12,016,875 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Astellas | IZERVAY | avacincaptad pegol sodium | SOLUTION;INTRAVITREAL | 217225-001 | Aug 4, 2023 | RX | Yes | Yes | 8,236,773 | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for avacincaptad pegol sodium
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 2897900 | AGENTS THERAPEUTIQUES A BASE D'APTAMERES UTILES DANS LE TRAITEMENT DE TROUBLES LIES AU COMPLEMENT (APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS) | ⤷ Subscribe |
| Eurasian Patent Organization | 201690212 | СПОСОБЫ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ОФТАЛЬМОЛОГИЧЕСКИХ ПАТОЛОГИЧЕСКИХ СОСТОЯНИЙ | ⤷ Subscribe |
| Hong Kong | 1256789 | 用於治療補體-相關失調的適體治療 (APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS) | ⤷ Subscribe |
| Canada | 2597889 | AGENTS THERAPEUTIQUES A BASE D'APTAMERES UTILES DANS LE TRAITEMENT DE TROUBLES LIES AU COMPLEMENT (APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS) | ⤷ Subscribe |
| China | 104404046 | Aptamer therapeutics useful in the treatment of complement-related disorders | ⤷ Subscribe |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
